Literature DB >> 14261530

MYELOMA PROTEINS AND THE CLINICAL RESPONSE TO MELPHALAN THERAPY.

D E DE BERGSAGEL, P J MIGLIORE, K M GRIFFITH.   

Abstract

Objective improvement after therapy with melphalan occurred in all patients producing only Bence Jones kappa proteins, in half of the patients with myeloma serum proteins, and in none of those producing only Bence Jones lambda proteins.

Entities:  

Keywords:  BENCE JONES PROTEIN; BLOOD PROTEINS; DRUG THERAPY; LEUKOPENIA; MELPHALAN; MULTIPLE MYELOMA; NEOPLASM STATISTICS; PROGNOSIS; TOXICOLOGIC REPORT

Mesh：

Substances：

Year:  1965        PMID： 14261530     DOI： 10.1126/science.148.3668.376

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  9 in total

1.  [The therapy of the paraproteinemias].

Authors:  U Kanzow
Journal:  Blut       Date:  1969-05

2.  Management of multiple myeloma.

Authors:  J S Malpas
Journal:  Br Med J       Date:  1969-04-19

3.  [Electrophoretical, class and group distribution of "paraproteins" and normal immunoglobulins].

Authors:  A Fateh-Moghadam; R Lamerz; M Knedel; B Tsirimbas
Journal:  Klin Wochenschr       Date:  1971-04-15

4.  IgD plasma cell neoplasia: clinical manifestations and characteristic features.

Authors:  W Pruzanski; I Rother
Journal:  Can Med Assoc J       Date:  1970-05-23       Impact factor: 8.262

5.  [Analysis of prognostic factors in plasmacytoma].

Authors:  W Gassmann; T Haferlach; N Schmitz; W Kayser; H H Euler; J Drews; H Löffler
Journal:  Klin Wochenschr       Date:  1984-10-01

6.  Multiple myeloma. Clinical correlation of immunoglobulin changes with therapy. A report of 23 cases.

Authors:  C M Basch; E H Rosenbaum
Journal:  Calif Med       Date:  1969-01

7.  Immunoglobulin synthesis and total body tumor cell number in IgG multiple myeloma.

Authors:  S E Salmon; B A Smith
Journal:  J Clin Invest       Date:  1970-06       Impact factor: 14.808

8.  Kinetics of tumor growth and regression in IgG multiple myeloma.

Authors:  P W Sullivan; S E Salmon
Journal:  J Clin Invest       Date:  1972-07       Impact factor: 14.808

9.  Report on the second myelomatosis trial after five years of follow-up. Medical Research Council's Working Party on Leukaemia in Adults.

Authors: 
Journal:  Br J Cancer       Date:  1980-12       Impact factor: 7.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.